The rate of seroconversion 15 days after documented SARS-COV2 on RT-PCR was therefore significantly lower in cancer patients versus HCWs (30% versus 71%, P ¼ 0.04). Importantly, six of the seven serodiagnostic-negative cancer patients had received cytotoxic therapy or major surgical intervention in the previous 4 weeks, compared with none of the five remaining patients (P ¼ 0.003). None of these patients died.In this series, 5 of 85 (5.9%) and 13 of 244 (5.4%) cancer patients and HCWs, respectively, had detectable Ab against COVID-19. However, cancer patients had a significantly lower detection rate of SARS-COV2 Ab 15 days or later after symptoms and RT-PCRþ testing. Anti-SARS-COV2 Ab were more often undetectable in patients receiving cancer treatments in the month before testing. Additional studies will be needed to confirm whether immune response to the virus is influenced by recent cancer treatments.

Since December 2019, coronavirus disease 2019 (COVID-19) has spread worldwide [1]. COVID-19 can cause acute kidney injury (AKI) [2]. A cohort study showed that development of AKI was associated with poor outcomes [3]. However, data regarding COVID-19 in patients with chronic kidney disease (CKD) are limited. We investigated if patients with CKD have a poorer prognosis of COVID-19. We also searched for prognostic factors associated with mortality in COVID-19 patients with CKD. We analyzed Mount Sinai Health System (MSHS) medical records up to March 29, 2020, using Epic SlicerDicer software. We extracted data from patients who had positive results for the COVID-19 reverse-transcription polymerase chain reaction (RT-PCR) test. The 10th revision of the International Statistical Classification of Diseases code system was used to identify medical conditions. p values were calculated by using a 2-tailed χ 2 test, risk ratio (RR), and odds ratios (OR) were calculated with 95% confidence intervals (CI). MSHS waived institutional review board approval * Takayuki Yamada

Nephrotic syndrome is known to cause venous thromboembolism (VTE) due to urine loss of antithrombin III and activation of the coagulation system. We hypothesized that the degree of proteinuria may predict the development of VTE. This was a retrospective case-controlled study of in-patients urban academic teaching hospital from April, 2007 to March, 2009 and who had undergone an imaging study for VTE. All radiology reports (N = 1,647) for CT angiography of chest and Doppler sonogram of extremities were reviewed. The following data were collected: race/ethnicity, degree of proteinuria on urinalysis, serum protein and albumin levels, risk factors for VTE and renal function. The study population consisted of 284 patients with VTE and 280 age/sex matched controls. Relative to those who did not have proteinuria, patients who tested positive for protein had a 3.4-fold increased risk of VTE (odds ratio (OR) 3.4, 95% confidence interval [2.4, 5.0]). The association was unchanged when adjusted for other risk factors. Patients with proteinuria may have an increased risk of venous thromboembolism.